HEOR

News

Samantha Roberts to replace Gillian Leng as CEO of NICE

Prof Gillian Leng's replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has been named as Dr Samantha Roberts, currently managing director for hea

News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

After three years of availability via the Cancer Drugs Fund (CDF), MSD's checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to pr

News

Wales is first UK country to fund GW's Epidyolex for tuberou...

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by

News

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

Eli Lilly's RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced non-small cell lung cancer (NSCLC) in England and Wales, within the Cancer D

News

NICE backs ViiV/J&J's six-per-year injection for HIV

People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable therapies developed by ViiV Healthcare and

News

Illustration of a nerve cell on a colored background with light effects

Drug-resistant epilepsy drug Ontozry backed by NICE

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm

Samantha Roberts to replace Gillian Leng as CEO of NICE

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

Wales is first UK country to fund GW's Epidyolex for tuberou...

After Scotland says no, NICE backs Lilly's Retsevmo for lung...

NICE backs ViiV/J&J's six-per-year injection for HIV

Drug-resistant epilepsy drug Ontozry backed by NICE

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

HEOR

Editor's Picks